Search All Jobs

Showing 1 of 1 Jobs

Senior Manager - Flow Cytometry

$160k - $175k/yr

San Bruno, CA, USA

Full-Time

Senior Manager

Flow Cytometry

Confirmed live in the last 24 hours

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops cell therapies for solid tumors

Compensation Overview

$160k - $175k/yr

+ Bonus + Equity Incentive Plan

Senior, Expert

San Bruno, CA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Required Skills
R
Data Analysis
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Lyell Immunopharma referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • BSc in Immunology, Molecular and Cell Biology, Cancer Biology or related field with a minimum of 13 years’ experience or an MSc in Immunology, Molecular and Cell Biology, Cancer Biology or related field with a minimum of 11 years’ experience or a PhD in Immunology, Molecular and Cell Biology, Cancer Biology or related field with a minimum of 6 years’ experience
  • Demonstrated understanding of, and ability to apply principles, concepts, practices and standards associated with analytical flow cytometry assay development/validation, panel design, and/or sample testing in a laboratory setting
  • Proven experience in using high-dimensional multi-color flow cytometry instruments (Cytek Aurora preferable) and expert in multi-color panel design and analysis
  • Expert in FlowJo and proven experience in analysis strategies for flow cytometry-based assays (knowledge of R scripting language considered a plus)
  • Demonstrated experience and understanding of techniques directly applicable to immune-oncology and/or CAR T research
  • Excellent oral and written communication and presentation skills
  • Critical thinking, high degree of ownership, strong organizational, and problem-solving skills and ability to quickly adapt to changing project
  • Self-motivated and driven to achieve milestones and exceed goals with minimal direction
  • Ability to work independently and collaboratively among cross-functional teams
  • Ability to work efficiently, prioritize workflow, meet deadlines and balance competing priorities
  • Excellent analytical skills and scientific/technical expertise
Responsibilities
  • Partner closely with scientists in pre-clinical and translational teams to ensure the generation of high-quality, reliable, reproducible flow cytometry data through optimal panel design, assay development and analysis, while ensuring its positive impact on research objectives
  • Ensure the maintenance of flow cytometry analyzers and sorters at peak operating condition by ensuring ongoing instrument maintenance, standardization, and quality assurance
  • Manage/oversee research associates including mentoring, development, and training
  • Ensure successful assay development, execution, and smooth operations of the flow core by maintaining antibody and other critical reagent inventory
  • Responsible for writing and reviewing protocols and technical documents and ensuring quality standards are met in research laboratory setting
  • Establish and standardize analysis strategies for flow cytometry-based assays and work with IT team for efficient data handling and storage
  • Support cell sorting for downstream next-gen sequencing-based assays to enable deeper characterization of CAR-T cells in the context of complex in-vitro and in-vivo models
  • Work closely and maintain productive relationships with process sciences team on complex flow cytometry assays for T cell characterization. Nurture productive and collegial relationships with all users
  • Engage in continuing scientific and technical education so that the latest expertise knowledge is available to meet challenges in cutting-edge CAR-T research
  • Train and assist new users with technical and operational procedures
Desired Qualifications
  • Knowledge of R scripting language considered a plus

Lyell Immunopharma develops advanced cell therapies aimed at treating solid tumors, which are cancerous tissue masses. The company focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. Their approach includes genetic and epigenetic reprogramming of T cells to address challenges like T cell exhaustion and the need for durable stemness, which allows T cells to renew and persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments specifically for solid tumors, utilizing a diverse product pipeline and proprietary technologies. Their goal is to push the limits of current cancer treatments and provide effective solutions for patients where traditional methods have not succeeded.

Company Size

201-500

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of ImmPACT Bio strengthens Lyell's CAR T-cell therapy pipeline.
  • Strategic platform license with MaxCyte accelerates development of cell-based therapeutics.
  • Consolidation of operations in Washington streamlines manufacturing and reduces costs.

What critics are saying

  • Closure of LA site may disrupt operations and affect employee morale.
  • Reliance on clinical trial success poses risk if results are unfavorable.
  • Integration challenges from ImmPACT Bio acquisition may dilute focus on existing projects.

What makes Lyell Immunopharma unique

  • Lyell focuses on T cell reprogramming to treat solid tumors effectively.
  • Their proprietary Gen-R and Epi-R platforms address T cell exhaustion and stemness.
  • Lyell's dual-targeting CAR T-cell therapies enhance treatment efficacy and application.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
BioSpace
Apr 7th, 2025
Lyell Cuts 73 Employees as Part of LA Site Closure

After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma is closing its Los Angeles manufacturing facility, eliminating dozens of jobs there.

Business News Today
Oct 25th, 2024
Lyell Immunopharma to acquire ImmPACT-are CAR T-cell therapies the future of oncology?

Lyell Immunopharma is making waves with its strategic acquisition of ImmPACT Bio, a move aimed at bolstering its T-cell therapy capabilities.

GlobeNewswire
Oct 24th, 2024
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s...

Seeking Alpha
Sep 10th, 2023
Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Lyell Immunopharma: once huge IPO now waiting for clinical data.

BioHealth Innovation
Jul 6th, 2023
Biohealth Innovation

ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.